Elan and Cambridge University form new research centre

By Admin
A research partnership and collaboration between the University of Cambridge in the UK and Irish pharmaceutical company Elan has been announced. Togeth...

A research partnership and collaboration between the University of Cambridge in the UK and Irish pharmaceutical company Elan has been announced.

Together the two will create a new research centre dedicated to investigating degenerative brain disorders such as Alzheimer’s and Parkinson’s and creating advanced therapies.

The Cambridge-Elan Centre for Research Innovation and Drug Discovery will be based at the University of Cambridge and Elan will be investing $10 million in the five year project, with an option to extend it by a further five years.

To read the latest edition of Healthcare Global, click here

Researchers from both organisations want to find out if there are any compounds which are capable of altering the behaviour of proteins associated with neurodegenerative disorders.

They are hopeful that if there are it will pave the way for the development of new treatments for illnesses like Alzheimer’s and Parkinson’s.

Elan's two decades of experience in Alzheimer's research and its depth in biology and model systems is an ideal base from which to form the Centre.

This will be partnered with Cambridge University’s pioneering contributions in the development of biophysical approaches to study the molecular basis of protein misfolding and aggregation and their links to disease.

Commenting on the new partnership, Elan’s Executive Vice President and Chief Scientific Officer,  Dale Schenk, said: “This agreement is a natural next step in the existing working relationship between our scientists in South San Francisco and scientists at the University of Cambridge.

“This collaborative effort complements our portfolio of programs in neuroscience and supports the process of discovery which we believe may lead to a class of therapeutics that no one has thought possible before.”

Our magazine is now available on the iPad. Click here to download it.


Featured Articles

TrueBinding’s antibody drugs fight Alzheimer’s Disease

Dongxu Sun, CEO at TrueBinding, shares how its research & antibody drug development is fighting illnesses such as Alzheimer’s Disease, stroke & more

Cardinal Health’s clinically integrated pharma supply chain

Peter Siavelis, SVP & General Manager, Health System and Provider Distribution & Services at Cardinal Health, discusses the integrated pharma supply chain

Healthcare Digital news roundup: digital healthcare & AI

This week in Healthcare Digital, we looked at digital skills for healthcare leaders, medical technology & acoustic AI used in digital cough monitoring

Hospitals must embrace IoMT device security


Mental health support for working women and mothers

Digital Healthcare

Digital evolution delivers better healthcare outcomes

Digital Healthcare